COVID-19 Pfizer-BioNTech BNT162b2 mRNA疫苗接种在5-17岁非免疫缺陷儿童和青少年中预防COVID-19相关急诊和紧急护理就诊及住院的有效性——VISION网络,10个州,2021年4月至2022年1月
VISION网络采用检测阴性病例对照设计,分析了2021年4月9日至2022年1月29日10个州5-17岁儿童和青少年中39,217次急诊和紧急护理就诊及1,699次住院。5-11岁儿童接种2剂后14-67天对急诊和紧急护理就诊的疫苗有效性为46%;12-15岁和16-17岁青少年接种2剂后14-149天分别为83%和76%,≥150天分别为38%和46%。16-17岁青少年接种第3剂后≥7天疫苗有效性增至86%。
要点
- 5-11岁儿童接种2剂BNT162b2后14-67天对COVID-19相关急诊和紧急护理就诊的疫苗有效性为46%。
- 12-15岁和16-17岁青少年接种2剂后14-149天疫苗有效性分别为83%和76%,≥150天分别降至38%和46%。
- 16-17岁青少年接种第3剂后≥7天疫苗有效性增至86%,奥密克戎主要流行期增至81%。
核心结论
- 所有符合条件的儿童和青少年应保持按推荐接种COVID-19疫苗,包括12-17岁者接种加强针。
研究设计与样本
- VISION网络与CDC合作,采用病例对照检测阴性设计,分析2021年4月9日至2022年1月29日10个州5-17岁COVID-19样疾病患者的39,217次急诊和紧急护理就诊及1,699次住院。
主要发现
- 5-11岁儿童接种2剂后14-67天对实验室确诊COVID-19相关急诊和紧急护理就诊的疫苗有效性为46%。
- 12-15岁和16-17岁青少年接种2剂后14-149天疫苗有效性分别为83%和76%,≥150天分别为38%和46%。
- 16-17岁青少年接种第3剂后≥7天疫苗有效性增至86%,奥密克戎主要流行期增至81%。
- 12-17岁青少年在奥密克戎主要流行期急诊和紧急护理就诊的疫苗有效性显著低于德尔塔主要流行期,奥密克戎流行期接种2剂后≥150天无显著保护。
- 整个研究期间,5-11岁儿童接种2剂后14-67天对实验室确诊COVID-19相关住院的疫苗有效性为74%,置信区间宽且包括零;12-15岁和16-17岁青少年接种2剂后14-149天分别为92%和94%,≥150天分别为73%和88%。
临床怎么用
- 所有符合条件的儿童和青少年应保持按推荐接种COVID-19疫苗,包括12-17岁者接种加强针。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose mRNA vaccine effectiveness (VE) in persons aged 12-17 years (referred to as adolescents in this report) have also indicated high levels of protection against SARS-CoV-2 (the virus that causes COVID-19) infection and COVID-19-associated hospitalization (4-6); however, data on VE against the SARS-CoV-2 B.1.1.529 (Omicron) variant and duration of protection are limited. Pfizer-BioNTech VE data are not available for children aged 5-11 years. In partnership with CDC, the VISION Network* examined 39,217 emergency department (ED) and urgent care (UC) encounters and 1,699 hospitalizations† among persons aged 5-17 years with COVID-19-like illness across 10 states during April 9, 2021-January 29, 2022,§ to estimate VE using a case-control test-negative design. Among children aged 5-11 years, VE against laboratory-confirmed COVID-19-associated ED and UC encounters 14-67 days after dose 2 (the longest interval after dose 2 in this age group) was 46%. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 83% and 76%, respectively; VE ≥150 days after dose 2 was 38% and 46%, respectively. Among adolescents aged 16-17 years, VE increased to 86% ≥7 days after dose 3 (booster dose). VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance. However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose. During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years.
引用
- Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35239634. doi:10.15585/mmwr.mm7109e3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。